Conditions: Type 2 Diabetes Mellitus
Keywords: insulin resistance
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 462
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.

Detailed description:

Arms:
arm 1: teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) arm 2: teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide arm 3: teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide arm 4: teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor

Interventions: intervention 1: teneligliptin intervention 2: glinide intervention 3: biguanide intervention 4: alpha-glucosidase inhibitor
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None intervention 4: None

Protocol document: